RiboBio Achieves New Milestone in Antithrombotic Pipeline: Submits Phase II Clinical Application for Novel siRNA Drug, Unlocking Further Potential of Oligonucleotide Therapeutics

May 28, 2026 · Suzhou, China Mölndal, Sweden

Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary, Ribocure Pharmaceuticals (collectively referred to as "Ribo Life Science"), announced that it has submitted a Phase II clinical trial application (CTA) to the European Medicines Agency (EMA) for RBD1119, a small nucleic acid drug for the treatment of coronary artery disease. Recently, based on RiboGalSTAR^TMLeveraging its liver-targeted siRNA platform, Ribo Life Science has concurrently advanced the clinical development of multiple siRNA therapeutics in niche indications including atrial fibrillation and venous thromboembolism, establishing a globally leading portfolio of anticoagulant/antithrombotic oligonucleotide drugs. This strategic pipeline aims to systematically address the fundamental treatment gap in thromboembolic diseases. The recent Clinical Trial Application (CTA) submission for coronary artery disease marks another significant milestone in Ribo Life Science's strategic expansion within the antithrombotic sector, underscoring the company's confidence in continuously broadening the application of oligonucleotide therapeutics in this field.

Coronary artery disease (CAD) is the leading cause of morbidity and mortality among patients with cardiovascular disease worldwide. Its primary underlying cause is the formation of atherosclerotic plaques and subsequent thrombotic complications, such as myocardial infarction and ischemic events. Currently, antiplatelet and anticoagulant therapies are standard clinical practices; however, in patients with stable CAD who have undergone optimal standard therapy, the risk of thrombotic events remains inadequately controlled. A major limitation of existing therapies—the elevated risk of bleeding—further constrains treatment intensity and long-term medication regimens for many patients. Therefore, to address the current challenges in antithrombotic management, there is an urgent need to develop novel therapeutic agents that can effectively and durably prevent thromboembolism while mitigating bleeding risk, thereby achieving an optimal balance between efficacy and safety.